Meeting
2017 Gastrointestinal Cancers Symposium
Anti-EGFR treatment for EGFR-amplified gastroesophageal adenocarcinoma.
Authors
Steven Brad Maron
University of Chicago, Chicago, IL
Steven Brad Maron , Lindsay Alpert , David Xu , Rachel Rendak , Emily O'Day , Namrata Setia , Daniel V.T. Catenacci
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach
Track
Cancers of the Esophagus and Stomach
Sub Track
Translational Research
Clinical Trial Registration Number
NCT01416714 / NCT02213289
Citation
J Clin Oncol 35, 2017 (suppl 4S; abstract 60)
DOI
10.1200/JCO.2017.35.4_suppl.60
Abstract #
60
Poster Bd #
F16
Abstract Disclosures
Similar Posters
Poster
2016 Genitourinary Cancers Symposium
Molecular profiling of non-urothelial bladder cancer: Adenocarcinoma and squamous cell carcinoma.
First Author: Daniel M. Geynisman
Poster
2024 ASCO Annual Meeting
Safety and anti-tumor activity of BAY 2927088 in patients with HER2-mutant NSCLC: Results from an expansion cohort of the SOHO-01 phase I/II study.
First Author: Nicolas Girard
Poster
2023 ASCO Annual Meeting
Phase I Beamion Lung 1 trial of BI 1810631, a HER2 tyrosine kinase inhibitor (TKI), as monotherapy in patients (pts) with advanced/metastatic solid tumors with HER2 aberrations: Updated data.
First Author: John Heymach
Poster
2023 ASCO Annual Meeting
Afatinib in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN) harboring alterations in the HER pathway: Results of the B1 cohort of the EORTC-HNCG-1559 trial (UPSTREAM).
First Author: Rachel Galot